Beacon Therapeutics’ Eye Gene Therapy Succeeds in Late Stage Trial

Beacon Therapeutics’ Eye Gene Therapy Succeeds in Late Stage Trial

Gene therapy biotech Beacon Therapeutics reports positive results in its pivotal Phase II/III trial of its AAV therapy for treatment of the rare eye disease X-linked retinitis pigmentosa.

Beacon's gene therapy for vision loss condition meets main trial goal ...

Beacon's XLRP gene therapy meets pivotal U.S. endpoint - European Biotechnology Magazine

Beacon Therapeutics' gene therapy laru-zova met its U.S. pivotal endpoint in X-linked retinitis pigmentosa, while results on the trial's separately designated European primary efficacy measure were less clear-cut.

Beacon gene therapy hits key goal in rare eye disease trial

Beacon’s laru-zova gene therapy improved low-light vision in a pivotal XLRP trial, paving the way for discussions with regulators.

Beacon's gene therapy for vision loss condition meets main trial goal

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.